Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice

• Published in: Journal of nanobiotechnology Vol. 22; no. 1; p. 27
• Main Authors: Abad, Catalina, Demeules, Mélanie, Guillou, Charlotte, Gondé, Henri, Zoubairi, Rachid, Tan, Yossan-Var, Pinto-Espinoza, Carolina, Schäfer, Waldemar, Mann, Anna Marei, Vouret-Craviari, Valérie, Koch-Nolte, Friedrich, Adriouch, Sahil
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.01.2024; BioMed Central; BMC
• Subjects: Adeno-associated virus; Analysis; Animal models; Animals; Antibodies; Antigens; Bioavailability; Biological Products; Care and treatment; Cell receptors; Chemokines; Chemokines - metabolism; Cloning; Colitis; Colitis - chemically induced; Colitis - drug therapy; Colon - metabolism; Cytokines; Cytokines - metabolism; Dendritic cells; Dependoviruses; Dextran; Dextrans; Disease Models, Animal; Expression vectors; Gene transfer; Genetic transformation; Genetic vectors; Health aspects; Histopathology; Immune system; In vivo methods and tests; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory diseases; Injection; Life Sciences; Lymphocytes; Medical research; Medicine, Experimental; Mice; Mice, Inbred C57BL; Modulation; Nanobodies; Nanobodies (VHH); Nanomedicine; P2X7; Sodium sulfate; Sulfates; Therapeutics, Experimental; France; Adeno-associated virus; Animal models; Colitis; P2X7; Nanobodies (VHH)
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-023-02285-4

The pro-inflammatory ATP-gated P2X7 receptor is widely expressed by immune and non-immune cells. Nanobodies targeting P2X7, with potentiating or antagonistic effects, have been developed. Adeno-associated virus (AAV)-mediated gene transfer represents an efficient approach to achieve long-term in vivo expression of selected nanobody-based biologics. This approach (AAVnano) was used to validate the relevance of P2X7 as a target in dextran sodium sulfate (DSS)-induced colitis in mice. Mice received an intramuscular injection of AAV vectors coding for potentiating (14D5-dimHLE) or antagonistic (13A7-Fc) nanobody-based biologics targeting P2X7. Long-term modulation of P2X7 activity was evaluated ex vivo from blood samples. Colitis was induced with DSS in mice injected with AAV vectors coding for nanobody-based biologics. Severity of colitis, colon histopathology and expression of chemokines and cytokines were determined to evaluate the impact of P2X7 modulation. A single injection of an AAV vector coding for 13A7-Fc or 14D5-dimHLE efficiently modulated P2X7 function in vivo from day 15 up to day 120 post-injection in a dose-dependent manner. An AAV vector coding for 13A7-Fc significantly ameliorated DSS-induced colitis and significantly reduced immune cell infiltration and expression of chemokines and proinflammatory cytokines in colonic tissue. We have demonstrated the validity of AAVnano methodology to modulate P2X7 functions in vivo. Applying this methodological approach to a DSS-induced colitis model, we have shown that P2X7 blockade reduces inflammation and disease severity. Hence, this study confirms the importance of P2X7 as a pharmacological target and suggests the use of nanobody-based biologics as potential therapeutics in inflammatory bowel disease.